Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
| Molecular Weight | 687.2 g/mol |
|---|---|
| Molecular Formula | C32H39ClN6O7S |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 10 |
| Exact Mass | 686.2289465 g/mol |
| Monoisotopic Mass | 686.2289465 g/mol |
| Topological Polar Surface Area | 200 Ų |
| Heavy Atom Count | 47 |
| Formal Charge | 0 |
| Complexity | 1090 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
ABOUT THIS PAGE
58
PharmaCompass offers a list of Conatumumab API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Conatumumab manufacturer or Conatumumab supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Conatumumab manufacturer or Conatumumab supplier.
PharmaCompass also assists you with knowing the Conatumumab API Price utilized in the formulation of products. Conatumumab API Price is not always fixed or binding as the Conatumumab Price is obtained through a variety of data sources. The Conatumumab Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Conatumumab manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Conatumumab, including repackagers and relabelers. The FDA regulates Conatumumab manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Conatumumab API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Conatumumab supplier is an individual or a company that provides Conatumumab active pharmaceutical ingredient (API) or Conatumumab finished formulations upon request. The Conatumumab suppliers may include Conatumumab API manufacturers, exporters, distributors and traders.
Conatumumab Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Conatumumab GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Conatumumab GMP manufacturer or Conatumumab GMP API supplier for your needs.
A Conatumumab CoA (Certificate of Analysis) is a formal document that attests to Conatumumab's compliance with Conatumumab specifications and serves as a tool for batch-level quality control.
Conatumumab CoA mostly includes findings from lab analyses of a specific batch. For each Conatumumab CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Conatumumab may be tested according to a variety of international standards, such as European Pharmacopoeia (Conatumumab EP), Conatumumab JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Conatumumab USP).
